B-FABP Inhibitors

B-FABP Inhibitors are a group of chemical entities designed to modulate the activity of B-FABP. The chemicals listed are not direct inhibitors of B-FABP but may influence its activity or expression indirectly through various metabolic pathways, particularly those involving fatty acid metabolism and peroxisome proliferator-activated receptors (PPARs). PPAR agonists such as GW7647, Fenofibrate, Rosiglitazone, Pioglitazone, Bezafibrate, Gemfibrozil, WY-14643, Elafibranor, Clofibrate, Ciglitazone, and L-165041 are known to play significant roles in lipid metabolism. These compounds can indirectly affect B-FABP function by altering the cellular environment related to fatty acid transport and metabolism. B-FABP is involved in binding and transporting fatty acids within cells, particularly in the brain, and its activity can be influenced by the overall state of lipid metabolism. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that can have various effects on inflammation and pain, along with impacts on fatty acid transport and signaling. Its presence and activity might indirectly influence B-FABP function.